Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | ELARA: tisa-cel shows promise for follicular lymphoma

David Maloney • 15 Dec 2020
ASH 2020
Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Tisagenlecleucel
ELARA JULIET

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses promising results from the ongoing Phase II ELARA trial (NCT03568461) investigating the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) for follicular lymphoma. Early data has shown that tisa-cel is well-tolerated and achieves durable complete remissions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from David Maloney

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
4:36
Highlights from the immunotherapy in CLL session
David Maloney • 20 Sep 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals